About The Coronavirus Immunotherapy Consortium
The Coronavirus Immunotherapy Consortium (CoVIC) operates as an academic-industry non-profit research collaboration for Coronavirus immunotherapies. It works to accelerate the discovery, optimization, and delivery of life-saving antibody-based therapeutics against SARS-CoV-2. The Coronavirus Immunotherapy Consortium was founded in 2020 and is based in La Jolla, California.
Missing: The Coronavirus Immunotherapy Consortium's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: The Coronavirus Immunotherapy Consortium's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
The Coronavirus Immunotherapy Consortium Frequently Asked Questions (FAQ)
When was The Coronavirus Immunotherapy Consortium founded?
The Coronavirus Immunotherapy Consortium was founded in 2020.
Where is The Coronavirus Immunotherapy Consortium's headquarters?
The Coronavirus Immunotherapy Consortium's headquarters is located at 9420 Athena Cir, La Jolla.
Who are The Coronavirus Immunotherapy Consortium's competitors?
Competitors of The Coronavirus Immunotherapy Consortium include Flow Pharma and 4 more.
Compare The Coronavirus Immunotherapy Consortium to Competitors
Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.
Effigene Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company developing small interference RNA (siRNA)-based therapeutics to treat various human diseases.
Exigent Pharmaceuticals is a new biopharmaceutical company focused on the development and commercialization of anti-infectives. Exigent is currently developing new pharmaceuticals to treat drug-resistant bacterial infections, using its technology platform.
Elara Pharmaceuticals is a Heidelberg, Germany-based biotech company focused on the development of drugs for the treatment of different cancers.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.